New Drug Approvals Fall in 2010 as Safety Concerns Slow U.S. FDA Decisions – Bloomberg

Having a good pipeline of new drugs in essential to keep medical progress going forward. This is especially true for infectious diseases as bacteria continually evolve the ability to resist current drugs. Unfortunately new antibiotic development is on the back burner for many drug companies, as it is seen as being to expensive to develop.

New Drug Approvals Fall in 2010 as Safety Concerns Slow U.S. FDA Decisions – Bloomberg.

Leave a Reply